Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · Real-Time Price · USD

0.1727

+0.0041 (2.43%)

At close: Sep 2, 2026, 4:00 PM EDT

0.1696

-0.0031 (-1.80%)

Pre-market: Sep 3, 2026, 8:30 AM EDT

Vivos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	20.9	17.44	15.03	13.8	16.02	16.89
Revenue Growth	45.22%	16.05%	8.91%	-13.87%	-5.10%	29.23%
Cost of Revenue	7.96	6.9	6.01	5.53	6.01	4.28
Gross Profit	12.94	10.54	9.02	8.27	10.02	12.6
Selling, General & Admin	33.7	29.13	19.61	24.95	34.18	31.34
Research & Development	-	-	-	-	0.2	-
Operating Expenses	35.49	30.44	20.19	25.57	35.05	32.08
Operating Income	-22.55	-19.89	-11.17	-17.3	-25.03	-19.47
Interest Expense	-2.2	-	-	-	-	-0.01
Other Non Operating Income (Expenses)	-1.27	-1.34	0.04	3.71	-0.1	0.11
EBT Excluding Unusual Items	-26.03	-21.23	-11.14	-13.58	-25.13	-19.38
Asset Writedown	-	-	-	-	-	-0.91
Other Unusual Items	0.4	-	-	-	1.29	-
Pretax Income	-25.63	-21.23	-11.14	-13.58	-23.85	-20.29
Earnings From Continuing Operations	-25.63	-21.23	-11.14	-13.58	-23.85	-20.29
Minority Interest in Earnings	0.17	0.06	-	-	-	-
Net Income	-25.46	-21.17	-11.14	-13.58	-23.85	-20.29
Net Income to Common	-25.46	-21.17	-11.14	-13.58	-23.85	-20.29
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	14	10	5	1	1	1
Shares Outstanding (Diluted)	14	10	5	1	1	1
Shares Change	72.97%	104.66%	311.68%	32.46%	8.39%	65.00%
EPS (Basic)	-1.83	-2.06	-2.22	-11.14	-25.90	-23.89
EPS (Diluted)	-1.83	-2.06	-2.22	-11.14	-25.90	-23.89
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-19.01	-17.6	-13.26	-12.8	-20.51	-18.13
Free Cash Flow Per Share	-1.36	-1.71	-2.64	-10.50	-22.28	-21.35
Gross Margin	61.90%	60.44%	60.00%	59.93%	62.52%	74.65%
Operating Margin	-107.90%	-114.05%	-74.32%	-125.32%	-156.21%	-115.31%
Profit Margin	-121.79%	-121.37%	-74.09%	-98.42%	-148.81%	-120.15%
Free Cash Flow Margin	-90.96%	-100.92%	-88.21%	-92.74%	-128.00%	-107.38%
EBITDA	-20.76	-18.59	-10.59	-16.68	-24.36	-18.74
EBITDA Margin	-99.33%	-106.55%	-70.45%	-120.82%	-152.03%	-110.97%
D&A For EBITDA	1.79	1.31	0.58	0.62	0.67	0.73
EBIT	-22.55	-19.89	-11.17	-17.3	-25.03	-19.47
EBIT Margin	-107.90%	-114.05%	-74.32%	-125.32%	-156.21%	-115.31%
Revenue as Reported	20.9	17.44	15.03	13.8	16.02	16.89

SEC Filings: 10-K · 10-Q